Токсический эпидермальный некролиз как вариант тяжелого поражения кожи при системной красной волчанке
https://doi.org/10.14412/1995-4484-2018-785-790
Аннотация
Об авторах
Л. Д. ВоробьеваРоссия
115522 Москва, Каширское шоссе, 34А.
Е. А. Асеева
Россия
115522 Москва, Каширское шоссе, 34А.
С. К. Соловьев
Россия
115522 Москва, Каширское шоссе, 34А.
Т. А. Белоусова
Россия
119991 Москва, ул. Трубецкая, 8, стр. 2.
Н. Е. Лопатина
Россия
115522 Москва, Каширское шоссе, 34А.
Е. Г. Сажина
Россия
115522 Москва, Каширское шоссе, 34А.
Г. В. Серикова
Россия
115522 Москва, Каширское шоссе, 34А.
Список литературы
1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-85. doi: 10.1056/NEJM199411103311906
2. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens – Johnson syndrome, toxic epidermal ecrolysis and hypersensitivity syndrome. Dermatol Online J. 2002;8(1):5.
3. Letko E, Papaliodis GN, Daoud YJ, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allerg Asthma Immunol. 2005;94(4):419-36. doi: 10.1016/S1081-1206(10)61112-X
4. Sharma VK, Jerajani HR, Srinivas CR, et al. Proposed IADVL Consensus Guidelines 2006: Management of Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). New Delhi: IADVL's Therapeutic Guidelines Committee; 2008.
5. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome and toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-9. doi: 10.1056/NEJM199512143332404
6. Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153(2):241-53. doi: 10.1111/j.1365-2133.2005.06721.x
7. Raj D, Brash DE, Grossman D. Keratinocyte apoptosis in epidermal development and disease. J Investigat Dermatol. 2006;126:243-57. doi: 10.1038/sj.jid.5700008
8. Leaute-Labreze C, Lamireau T, Chawki D, et al. Diagnosis, classification, and management of erythema multiforme and Stevens–Johnson syndrome. Arch Dis Child. 2000;83:347-52. doi: 10.1136/adc.83.4.347
9. Harr T, French LE. Toxic epidermal necrolysis and Stevens–Johnson syndrome. Orphan J Rare Dis. 2010;5:39-40. doi: 10.1186/1750-1172-5-39
10. Жерносек ВФ, Дюбкова ТП. Синдром Стивенса–Джонсона – токсический эпидермальный некролиз у детей. Часть I. Определение, этиология, патогенез, клинические проявления, системное лечение. Педиатрическая фармакология. 2011;8(1):30-8 [Zhernosek VF, Dyubkova TP. Stevens-Johnson syndrome – toxic epidermal necrolysis in children. Part I. Definition, etiology, pathogenesis, clinical manifestations, systemic treatment. Pediatricheskaya Farmakologiya. 2011;8(1):30-8 (In Russ.)].
11. Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens–Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007;62:527-31. doi: 10.1111/j.1398-9995.2006.01295.x
12. Gilliam JN, Sontheimer RD. Skin manifestations of SLE [Review]. Clin Rheum Dis. 1982;8:207-18.
13. Sontheimer RD. Subacute cutaneous lupus erythematosus. Clin Dermatol. 1985;3:58-68. doi: 10.1016/0738-081X(85)90078-1
14. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B. Current Perspectives on Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allerg Immunol. 2017 Nov 29;54(1):147-76. doi: 10.1007/s12016-017-8654-z
15. Gilliam IN. The cutaneous signs of lupus erythematosus. Contin Educ Fam Phys. 1977;6:34-70.
16. Sayag J, Mongin M, Weiller PJ, et al. Toxic epidermic necrolysis in acute disseminated lupus erythematosus. Ann Dermatol Venereol. 1980;107(11):1077-81.
17. Chan HL. Observations on drug-induced toxic epidermal necrolysis in Singapore. J Am Acad Dermatol. 1984;10(6):973-8. doi: 10.1016/S0190-9622(84)80317-5
18. Burge SM, Dawber RP. Stevens–Johnson syndrome and toxic epidermal necrolysis in a patient with systemic lupus erythematosus [letter]. J Am Acad Dermatol. 1985;13:665-6. doi: 10.1016/S0190-9622(85)80447-3
19. Bielsa I, Herrero C, Font J, Mascaro JM. Lupus erythematosus and toxic epidermal necrolysis [letter]. J Am Acad Dermatol. 1987;16(6):1265-7. doi: 10.1016/S0190-9622(87)80031-2
20. Ting W, Stone M, Racila D, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus. 2004;13(12):941-50. doi: 10.1191/0961203304lu2037sa
21. Mutasim DF. Severe subacute cutaneous lupus erythematosus presenting with generalized erythroderma and bullae. J Am Acad Dermatol. 2003;48:947-9. doi: 10.1067/mjd.2003.244
22. Kelly JP, Auquier A, Rzany B, et al. An international collaborative casecontrol study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol. 1995;48:1099-108. doi: 10.1016/0895-4356(95)00004-N
23. Maldelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: A novel manifestation of lupus? J Am Acad Dermatol. 2003;48:525-9. doi: 10.1067/mjd.2003.107
24. Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctivebut immunologically heterogeneous bullous disorder. J Invest Dermatol. 1993;100:285-345. doi: 10.1111/1523-1747.ep12355210
25. Махнева НВ, Давиденко ЕБ, Белецкая ЛВ. О проблеме диагностики и дифференциальной диагностики аутоиммунной пузырчатки. Альманах клинической медицины. 2014;34:9-14 [Makhneva NV, Davidenko EB, Beletskaya LV. On the problem of diagnosis and differential diagnosis of autoimmune pemphigus. Al'manakh Klinicheskoy Meditsiny. 2014;34:9-14 (In Russ.)].
26. Yung A, Oakley A. Bullous systemic lupus erythematosus. Australas J Dermatol. 2000;41(4):234-7. doi: 10.1046/j.1440-0960.2000.00426.x
27. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-3. doi: 10.1126/science.282.5388.490
28. Kazatchkine MD, Kaveri SV. Advances in immunology: immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747-55. doi: 10.1056/NEJMra993360
29. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding. Int Immunopharmacol. 2006;6:543-9. doi: 10.1016/j.intimp.2005.11.012
30. Fine JD. Management of acquired bullous skin diseases. N Engl J Med. 1995;333(22):1475-84. doi: 10.1056/NEJM199511303332207
31. Roujeau JC, Stern RS. Medical progress: severe adverse cutaneous reactions to drugs. NEJM. 1994;331(19):1272-85. doi: 10.1056/NEJM199411103311906
Рецензия
Для цитирования:
Воробьева Л.Д., Асеева Е.А., Соловьев С.К., Белоусова Т.А., Лопатина Н.Е., Сажина Е.Г., Серикова Г.В. Токсический эпидермальный некролиз как вариант тяжелого поражения кожи при системной красной волчанке. Научно-практическая ревматология. 2018;56(6):785-790. https://doi.org/10.14412/1995-4484-2018-785-790
For citation:
Vorobyeva L.D., Aseeva E.A., Solovyev S.K., Belousova T.A., Lopatina N.E., Sazhina E.G., Serikova G.V. Toxic epidermal necrolysis as a variant of severe skin lesions in systemic lupus erythematosus. Rheumatology Science and Practice. 2018;56(6):785-790. (In Russ.) https://doi.org/10.14412/1995-4484-2018-785-790